Mammoth deal connects dots in Bayer’s growing cell, gene therapy business

Bayer is adding a new gene editing technology to its expanding cell and gene therapy business through a deal with Jennifer Doudna-founded CRISPR play Mammoth, and it’s a technology that could complement its other platforms.

The companies teamed up in a deal announced Monday to develop in vivo gene editing therapies based on Mammoth’s mini CRISPR systems, with an initial focus on liver diseases, for five pre-selected indications. Bayer also has a non-exclusive option to the technology for ex vivo editing applications...